IP Library Granted Patent US 11,571,518
Granted Patent B2
US 11,571,518 · App. 16/422,639 · Granted Feb 7, 2023

Emergency devices

Inventors: Mark J. Flather (San Diego, CA); Karen K. Daniels (San Diego, CA); Thomas Moll (San Diego, CA)
Assignee: Adamis Pharmaceuticals Corporation
A61M5/281A61K31/485A61M5/20A61M2005/3125
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,571,518
App. No.
16/422,639
Granted
Feb 7, 2023
Kind
B2
Abstract

Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose.

Claims (30)

1. An emergency syringe device comprising:

a syringe including a therapeutic dose of at least one opioid antagonist, and a stopper; and

a plunger assembly including a plunger rod, an actuator including at least one guide rail, and a spacer, wherein the at least one guide rail travels against a front surface of the spacer,

wherein the plunger assembly is configured to move the stopper a predetermined distance without a user touching the plunger rod or being able to retract the plunger rod.

2. The syringe device of claim 1 , wherein the plunger assembly is configured to provide substantially identical doses of the at least one opioid antagonist even if more or less opioid antagonist is provided in the syringe by moving the stopper a predetermined distance.

3. The syringe device of claim 1 , further including:

an encasement configured to house the syringe.

4. The syringe device of claim 3 , wherein the encasement includes a window configured to allow the user to view the at least one opioid antagonist in the syringe.

5. The syringe device of claim 3 , wherein the encasement includes a needle guard configured to allow the user to cover a needle associated with the syringe after use.

6. The syringe device of claim 1 , wherein the at least one opioid antagonist is naloxone, a salt thereof, a derivative thereof, or a prodrug thereof.

7. The syringe device of claim 1 , wherein the at least one opioid antagonist is naloxone.

8. The syringe device of claim 6 , wherein the syringe device is configured to deliver about 5 mg of naloxone or a salt thereof.

9. The syringe device of claim 6 , wherein the syringe device is configured to deliver about 15 mg of naloxone or a salt thereof.

10. The syringe device of claim 1 , wherein the actuator and the spacer are configured to be secured around the plunger rod.

11. The syringe device of claim 1 , wherein the actuator includes a finger depression location.

12. The syringe device of claim 1 configured for use in an opioid overdose.

13. A method for administering a therapeutic dose of at least one opioid antagonist, the method comprising:

providing an emergency syringe device;

advancing a stopper on the syringe device through a syringe including the therapeutic dose of the at least one opioid antagonist;

wherein the stopper is only advanced a predetermined distance by a plunger assembly including a plunger rod, an actuator including at least one guide rail, and a spacer, wherein the at least one guide rail travels against a front surface of the spacer,

wherein the plunger assembly is configured to move the stopper without a user touching the plunger rod.

14. The method of claim 13 , wherein the syringe is housed in an encasement.

15. The method of claim 14 , wherein the encasement includes a window configured to allow the user to view the at least one opioid antagonist in the syringe.

16. The method of claim 14 , wherein the encasement includes a needle guard configured to allow the user to cover a needle after use.

17. The method of claim 13 , wherein the at least one opioid antagonist is naloxone, a salt thereof, a derivative thereof, or a prodrug thereof.

18. The method of claim 17 , wherein the at least one opioid antagonist is naloxone.

19. The method of claim 13 , wherein the actuator and the spacer are configured to be secured around the plunger rod and provide the predetermined distance.

20. The method of claim 13 , wherein the actuator and the spacer are configured to provide the predetermined distance between a start point and an end point.

21. The method of claim 13 , wherein the advancing of the stopper the predetermined distance is configured to deliver about 5 mg of naloxone or a salt thereof.

22. The method of claim 13 , wherein the advancing of the stopper the predetermined distance is configured to deliver about 100 mg of naloxone or a salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: DMK PHARMACEUTICAL CORPORATION
To: ZMI PHARMA INC.
Reel/Frame 068005/0373 →
CHANGE OF NAME Recorded Sep 28, 2023
From: ADAMIS PHARMACEUTICALS CORPORATION
To: DMK PHARMACEUTICALS CORPORATION
Reel/Frame 065082/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: FLATHER, MARK J.; DANIELS, KAREN K.; MOLL, THOMAS
To: ADAMIS PHARMACEUTICALS CORPORATION
Reel/Frame 050846/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: FLATHER, MARK J.; DANIELS, KAREN K.; MOLL, THOMAS
To: ADAMIS PHARMACEUTICALS CORPORATION
Reel/Frame 050180/0734 →
Continuity (2)
Provisional Application 62676742 · May 25, 2018
Related Publication 20190358403A1 · Nov 28, 2019
Cited By (2)
US 12,329,610 US 12,350,473